Clinical Trial: Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes
Brief Summary: Toxicity of anti-IL-5
Detailed Summary: The purpose of the study is to assess the toxicity of anti-IL-5, and to see whether it lowers peripheral blood eosinophils and/or tissue and whether it has a steroid and/or interferon sparing effect.
Sponsor: Children's Hospital Medical Center, Cincinnati
Current Primary Outcome: To assess the toxicity of anti-IL-5 in patients with hypereosinophilia [ Time Frame: 8 years ]
Original Primary Outcome: To assess the toxicity of anti-IL-5 in patients with hypereosinophilia
Current Secondary Outcome:
- To assess whether anti-IL-5 lowers peripheral blood eosinophils and/or tissue in patients with hypereosinophilia [ Time Frame: 8 years ]
- To assess whether anti-IL-5 has a steroid and/or interferon sparing effect [ Time Frame: 8 years ]
Original Secondary Outcome:
- To assess whether anti-IL-5 lowers peripheral blood eosinophils and/or tissue in patients with hypereosinophilia
- To assess whether anti-IL-5 has a steroid and/or interferon sparing effect
Information By: Children's Hospital Medical Center, Cincinnati
Dates:
Date Received: December 15, 2005
Date Started: December 2001
Date Completion:
Last Updated: January 20, 2017
Last Verified: January 2017
